Kyle Rasbach, PhD, PharmD, serves as a Managing Director for Eventide Ventures and a Senior Research Analyst for other Eventide investments. Dr. Rasbach has extensive experience in clinical pharmacology, basic science and health care equity research. Prior to joining Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm that invests across biotechnology, biopharmaceuticals, drug delivery and medical devices.
Earlier in his career, he was an equity research analyst and Vice President at T. Rowe Price, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments. Prior to joining T. Rowe, Dr. Rasbach was an equity research associate and Vice President at Cowen and Company, where he covered global pharmaceutical equities.
Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences as well as a PharmD from the Medical University of South Carolina; he completed his postdoctoral training in the laboratory of Bruce Spiegelman at the Harvard Medical School. He also holds an MBA from The Citadel and a BS in Biology from Denison University.
Email: info@eventideinvestments.com | Website: www.eventideinvestments.com
LinkedIn: www.linkedin.com/company/eventideassetmanagement | YouTube: www.youtube.com/EventideAssetManagement
